DOCSLIB.ORG

Healthpac Formulary Current As of July 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Healthpac Formulary Current As of July 2017 HealthPAC Formulary Current as of July 2017 Brand Name Generic Name Strength Class I Class II Aclovate Alclometasone Cream 45 gm Anti-inflammatory Agents Aclovate Alclometasone Ointment 45 gm Anti-inflammatory Agents Actigall Ursodiol 300 mg GI Actos Pioglitazone hydrochloride 15 mg Diabetes Thiazolidinediones Actos Pioglitazone hydrochloride 30 mg Diabetes Thiazolidinediones Actos Pioglitazone hydrochloride 45 mg Diabetes Thiazolidinediones Adderall XR Dextroamphetamine/amphetamine 10 mg Psychiatric Stimulant Adderall XR Dextroamphetamine/amphetamine 15 mg Psychiatric Stimulant Adderall XR Dextroamphetamine/amphetamine 20 mg Psychiatric Stimulant Adderall XR Dextroamphetamine/amphetamine 30 mg Psychiatric Stimulant Alaway Ketotifen 0.025% Ophthalmic Aldactone Spironolactone 25 mg Cardiovascular Diuretics Aldactone Spironolactone 50 mg Cardiovascular Diuretics Aldactone Spironolactone 100 mg Cardiovascular Diuretics Aldomet Methyldopa 250 mg Cardiovascular Central Alpha Agonist Aldomet Methyldopa 500 mg Cardiovascular Central Alpha Agonist Alphagan Brimonidine tartrate solution 0.2% Ophthalmic Glaucoma Amikin Amikacin 1000 mg/4 ml (4 cc) Antimicrobials Aminoglycoside Amikin Amikacin 500 mg/2 ml (2 cc) Antimicrobials Aminoglycoside Ambien Zolpidem 10 mg Psychiatric Hypnotic Ambien Zolpidem 5 mg Psychiatric Hypnotic Amoxil Amoxicillin 125 mg/5 ml (80 cc) Antimicrobials Penicillins Amoxil Amoxicillin 250 mg Antimicrobials Penicillins Amoxil Amoxicillin 250 mg/5 ml (150 cc) Antimicrobials Penicillins Amoxil Amoxicillin 400 mg/5 ml Antimicrobials Penicillins Amoxil Amoxicillin 500 mg Antimicrobials Penicillins Anafranil Clomipramine 25 mg Psychiatric Antidepressant Anafranil Clomipramine 50 mg Psychiatric Antidepressant Anafranil Clomipramine 75 mg Psychiatric Antidepressant Antivert Meclizine 25 mg tabs Neurologic Misc Apresoline Hydralazine 10 mg Cardiovascular Other Vasodilators Apresoline Hydralazine 100 mg Cardiovascular Other Vasodilators Apresoline Hydralazine 25 mg Cardiovascular Other Vasodilators Disclaimer: Doses / routes of administration are the responsibility of the prescribing provider based on the medical home's practice guidelines. Page 1 of 24 HealthPAC Formulary Current as of July 2017 Brand Name Generic Name Strength Class I Class II Apresoline Hydralazine 50 mg Cardiovascular Other Vasodilators Artane Trihexyphenidyl 2 mg Neurologic Parkinson Artane Trihexyphenidyl 2 mg/5 ml Neurologic Parkinson Artane Trihexyphenidyl 5 mg Neurologic Parkinson Asacol Mesalamine 400 mg GI Anti-inflammatory bowel Atarax Hydroxyzine HCL 10 mg Cold, Cough, Allergy Antihistamine Atarax Hydroxyzine HCL 10 mg/5 ml (120 cc) Cold, Cough, Allergy Antihistamine Atarax Hydroxyzine HCL 25 mg Cold, Cough, Allergy Antihistamine Atarax Hydroxyzine HCL 50 mg Cold, Cough, Allergy Antihistamine Ativan Lorazepam (SCH IV) 0.5 mg Psychiatric Benzos Ativan Lorazepam (SCH IV) 1 mg Psychiatric Benzos Ativan Lorazepam (SCH IV) 2 mg Psychiatric Benzos Atrovent Ipratropium MDI 18mcg/dose MDI (14gm) Respiratory Asthma Atrovent Inh Sol Ipratropium bromide 0.02% 500 mcg (3 cc/amp) Respiratory Nebulizer soln Augmentin Amoxicillin-clavulanate 200 mg/5 ml (100 cc) Antimicrobials Penicillins Augmentin Amoxicillin-clavulanate 500 mg-125 mg Antimicrobials Penicillins Augmentin Amoxicillin-clavulanate 875 mg-125 mg Antimicrobials Penicillins Antipyrene, Benzocaine, Glycerine Auralgan 10 ml drops Otic dehyd Avelox Moxifloxacin 400 mg Antimicrobials Quinolones Aygestin Norethindrone 5 mg Hormone Replacement Progestins Azopt Brinzolamide 1% suspension Ophthalmic Glaucoma Azulfidine Sulfasalazine 500 mg GI Anti-inflammatory bowel 40mg / 5ml - 200mg / 5- Bactrim Sulfamethxzl Trimethoprim Antimicrobials Sulfas ml (60 ml) Bactroban Mupirocin 2% ointment Derm Antimicrobial Benadryl Diphenhydramine 12.5 mg/ 5ml Cold, Cough, Allergy Antihistamine Benadryl Diphenhydramine 25, 50 mg capsules Cold, Cough, Allergy Antihistamine Benadryl Diphenhydramine 50 mg/ml (inj) Cold, Cough, Allergy Antihistamine Benemid Probenecid 500 mg Gout Bentyl Dicyclomine 10 mg GI Antispasmodics Bentyl Dicyclomine 20 mg GI Antispasmodics Biaxin Clarithromycin 500 mg Antimicrobials Disclaimer: Doses / routes of administration are the responsibility of the prescribing provider based on the medical home's practice guidelines. Page 2 of 24 HealthPAC Formulary Current as of July 2017 Brand Name Generic Name Strength Class I Class II Biltricide Praziquantel 600 mg Anthelmintics BuSpar Buspirone HCI 10 mg Psychiatric Other BuSpar Buspirone HCI 15 mg Psychiatric Other BuSpar Buspirone HCI 30 mg Psychiatric Other BuSpar Buspirone HCI 5 mg Psychiatric Other Butrans Buprenorphine 10 mcg/hr Analgesic Opiate Agonist Butrans Buprenorphine 15 mcg/hr Analgesic Opiate Agonist Butrans Buprenorphine 5 mcg/hr Analgesic Opiate Agonist Butrans Buprenorphine 7.5 mcg/hr Analgesic Opiate Agonist Byetta Exenatide 10 mcg/0.04 mL (2.4 mL) Diabetes GLP-1 Receptor Agonist Byetta Exenatide 5 mcg/0.02 mL (1.2 mL) Diabetes GLP-1 Receptor Agonist Calcium Channel Calan SR Verapamil SR 120 mg Cardiovascular Blockers Calcium Channel Calan SR Verapamil SR 180 mg Cardiovascular Blockers Calcium Channel Calan SR Verapamil SR 240 mg Cardiovascular Blockers Calciferol Vitamin D 50,000 units Vitamin Capoten Captopril 100 mg Cardiovascular ACE Inhibitor Capoten Captopril 12.5 mg Cardiovascular ACE Inhibitor Capoten Captopril 25 mg Cardiovascular ACE Inhibitor Capoten Captopril 50 mg Cardiovascular ACE Inhibitor Carafate Sucralfate 1 Gm GI Calcium Channel Cardizem Diltiazem 120 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 120 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 180 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 240 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 30 mg Cardiovascular Blockers Disclaimer: Doses / routes of administration are the responsibility of the prescribing provider based on the medical home's practice guidelines. Page 3 of 24 HealthPAC Formulary Current as of July 2017 Brand Name Generic Name Strength Class I Class II Calcium Channel Cardizem CD Diltiazem CD 300 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 360 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 60 mg Cardiovascular Blockers Calcium Channel Cardizem CD Diltiazem CD 90 mg Cardiovascular Blockers Cardizem CD, Calcium Channel Dilacor Xr, Cartia Diltiazem 60 mg Cardiovascular Blockers XL, Dilt-CD Cardizem CD, Calcium Channel Dilacor Xr, Cartia Diltiazem 90 mg Cardiovascular Blockers XL, Dilt-CD Calcium Channel Cardizem LA Dilitiazem HCI 180 mg Cardiovascular Blockers Calcium Channel Cardizem SR Diltiazem SR 120 mg Cardiovascular Blockers Calcium Channel Cardizem SR Diltiazem SR 180 mg Cardiovascular Blockers Calcium Channel Cardizem SR Diltiazem SR 240 mg Cardiovascular Blockers Calcium Channel Cardizem SR Diltiazem SR 300 mg Cardiovascular Blockers Cardura Doxazosin mesylate 1 mg Cardiovascular Alpha-1 blocker Cardura Doxazosin mesylate 2 mg Cardiovascular Alpha-1 blocker Cardura Doxazosin mesylate 4 mg Cardiovascular Alpha-1 blocker Cardura Doxazosin mesylate 8 mg Cardiovascular Alpha-1 blocker Catapres Clonidine HCI tabs 0.1 mg Cardiovascular Central Alpha Agonist Catapres Clonidine HCI tabs 0.2 mg Cardiovascular Central Alpha Agonist Catapres Clonidine HCI tabs 0.3 mg Cardiovascular Central Alpha Agonist Celebrex Celecoxib 100 mg Analgesic NSAID Celebrex Celecoxib 200 mg Analgesic NSAID Disclaimer: Doses / routes of administration are the responsibility of the prescribing provider based on the medical home's practice guidelines. Page 4 of 24 HealthPAC Formulary Current as of July 2017 Brand Name Generic Name Strength Class I Class II Celebrex Celecoxib 400 mg Analgesic NSAID Celebrex Celecoxib 50 mg Analgesic NSAID Celexa Citalopram Hydrobromide 10 mg Psychiatric Antidepressant Celexa Citalopram Hydrobromide 10 mg/5 ml Psychiatric Antidepressant Celexa Citalopram Hydrobromide 20 mg Psychiatric Antidepressant Celexa Citalopram Hydrobromide 40 mg Psychiatric Antidepressant Ciloxan Ciprofloxacin eye drop 0.3% Ophthalmic Cipro Ciprofloxacin 250 mg Antimicrobials Quinolones Cipro Ciprofloxacin 500 mg Antimicrobials Quinolones Claritin Loratadine 10 mg Antihistamine Cleocin Clindamycin 150 mg Antimicrobials Misc Cleocin Clindamycin 300 mg Antimicrobials Misc Cleocin Clindamycin topical gel, lotion 1% Derm Acne Cleocin-T Clindamycin topical solution 1% (60 ml) Derm Acne Clinoril Sulindac 150 mg Analgesic NSAID Clinoril Sulindac 200 mg Analgesic NSAID Cogentin Benztropine mesylate 0.5 mg Neurologic Parkinson Cogentin Benztropine mesylate 1 mg Neurologic Parkinson Cogentin Benztropine mesylate 1 mg/ml (inj) Neurologic Parkinson Cogentin Benztropine mesylate 2 mg Neurologic Parkinson Colcrys Colchicine 0.6 mg Gout Combivent MDI Albuterol-ipratropium Inhaler Respiratory Compazine Prochlorperazine 10 mg GI Antiemetic Compazine Prochlorperazine 25 mg supp GI Antiemetic Compazine Prochlorperazine 5 mg GI Antiemetic Cordarone Amiodarone 200 mg Cardiovascular Antiarrythmic Cordarone Amiodarone 400 mg Cardiovascular Antiarrythmic Coreg Carvedilol 12.5 mg Cardiovascular Beta Blockers Coreg Carvedilol 25 mg Cardiovascular Beta Blockers Coreg Carvedilol 3.125 mg Cardiovascular Beta Blockers Coreg Carvedilol 6.25 mg Cardiovascular Beta Blockers Cortizone Hydrocortisone cream 2.5% Derm Antiinflammatory Cortizone Hydrocortisone ointment 2.5% Derm Antiinflammatory Disclaimer: Doses / routes of administration are the responsibility of the prescribing
Load more

Recommended publications
  • 2020 Prior Authorization Criteria
    2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (1), 53-56 Different beta-blocking effects of carvedilol and bisoprolol in humans Koshucharova G, Klein W, Lercher P, Maier R, Stepan V Stoschitzky K, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Different Beta-Blocking Effects of Carvedilol and Bisoprolol J Clin Basic Cardiol 2001; 4: 53 Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans G. Koshucharova, R. Zweiker, R. Maier, P. Lercher, V. Stepan, W. Klein, K. Stoschitzky Bisoprolol is a beta1-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockade of alpha1-adrenoceptors. Administration of bisoprolol has been shown to cause up-regulation of β-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. The objective of the present study was to investigate beta-blocking effects of bisoprolol and carvedilol in healthy subjects. We compared the effects of single oral doses of clinically recommended amounts of bisoprolol (2.5, 5 and 10 mg) and carvedilol (25, 50 and 100 mg) to those of placebo in a randomised, double-blind, cross-over study in 12 healthy male volun- teers. Three hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min. of exercise, and after 15 min.
    [Show full text]
  • Tall Man Lettering List REPORT DECEMBER 2013 1
    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • Carvedilol an 3.125, 6.25, 12.5 & 25 Mg Tablets
    Carvedilol AN 3.125, 6.25, 12.5 & 25 mg tablets Carvedilol AN Consumer Medicine Information What is in this leaflet Heart Failure: Carvedilol AN helps to lower your Heart failure occurs when the heart blood pressure. can no longer pump blood strongly This leaflet answers some of the Your doctor may have prescribed enough for the body's needs. Often common questions about Carvedilol Carvedilol AN for another reason. AN. It does not contain all the the heart grows in size to try to available information. It does not improve the blood flow but this can Ask your doctor if you have any take the place of talking to your make the heart failure worse. questions about why Carvedilol AN has been prescribed for you. doctor or pharmacist. Symptoms of heart failure include All medicines have risks and shortness of breath and swelling of benefits. Your doctor has weighed the feet or legs due to fluid build-up. the possible risks of Carvedilol AN Carvedilol AN reduces the pressure Before you take against the expected benefits. that the heart has to pump against as Carvedilol AN If you have any concerns about this well as controlling your heart rate. medicine talk to your doctor or Over 6 months or more this will pharmacist. reduce the size of an oversized heart When you must not take and increase its efficiency. Keep this leaflet until you have Cervedilol AN Carvedilol AN reduces the chances finished treatment with the You must not take Carvedilol AN medicine. of you being admitted to hospital if: You may need to read it again.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]
  • Summary of Product Characteristics, Labelling and Package Leaflet
    SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 1 SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Carivalan 6.25 mg/5 mg film-coated tablets [Carivalan 6.25 mg/7.5 mg film-coated tablets] [Carivalan 12.5 mg/5 mg film-coated tablets] [Carivalan 12.5 mg/7.5 mg film-coated tablets] [Carivalan 25 mg/5 mg film-coated tablets] [Carivalan 25 mg/7.5 mg film-coated tablets] 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 6.25 mg of carvedilol and 5 mg of ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride). [Each film-coated tablet contains 6.25 mg of carvedilol and 7.5 mg of ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride] [Each film-coated tablet contains 12.5 mg of carvedilol and 5 mg of ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride] [Each film-coated tablet contains 12.5 mg of carvedilol and 7.5 mg of ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride] [Each film-coated tablet contains 25 mg of carvedilol and 5 mg of ivabradine (equivalent to 5.390 mg ivabradine as hydrochloride] [Each film-coated tablet contains 25 mg of carvedilol and 7.5 mg of ivabradine (equivalent to 8.085 mg ivabradine as hydrochloride] Excipient with known effect: lactose monohydrate (68.055 mg for Carivalan 6.25/5 mg, 65.360 mg for Carivalan 6.25/7.5 mg, 78.710 mg for Carivalan 12.5/5 mg, 76.015 mg for Carivalan 12.5/7.5 mg, 85.530 mg for Carivalan 25/5 mg and 82.835 mg for Carivalan 25/7.5 mg).
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • IEHP Dualchoice Cal Mediconnect Formulary Maintenance Drug List
    IEHP DualChoice Cal MediConnect (Medicare-Medicaid Plan) Formulary Maintenance Drug List The following formulary medications may be approvable up to a three-month supply. Certain medications on this list may require prior approval from the plan based on existing criteria before being covered. For coverage information please see our formulary located on our website. BRAND GENERIC STREGTH DOSAGE FORM ABACAVIR ABACAVIR SULFATE 300 MG TABLET ABACAVIR ABACAVIR SULFATE 20 MG/ML SOLUTION TRIUMEQ ABACAVIR SULFATE/DOLUTEGRAVIR 600-50-300 TABLET SODIUM/LAMIVUDINE ABACAVIR-LAMIVUDINE ABACAVIR SULFATE/LAMIVUDINE 600-300MG TABLET ABACAVIR-LAMIVUDINE- ABACAVIR SULFATE/LAMIVUDINE/ZIDOVUDINE 150-300 MG TABLET ZIDOVUDINE TYMLOS ABALOPARATIDE 80MCG/DOSE PEN INJCTR ORENCIA ABATACEPT 125 MG/ML SYRINGE ORENCIA CLICKJECT ABATACEPT 125 MG/ML AUTO INJCT ORENCIA ABATACEPT 50MG/0.4ML SYRINGE ORENCIA ABATACEPT 87.5MG/0.7 SYRINGE VERZENIO ABEMACICLIB 50 MG TABLET VERZENIO ABEMACICLIB 100 MG TABLET VERZENIO ABEMACICLIB 150 MG TABLET VERZENIO ABEMACICLIB 200 MG TABLET ABIRATERONE ACETATE ABIRATERONE ACETATE 500 MG TABLET ABIRATERONE ACETATE ABIRATERONE ACETATE 250 MG TABLET YONSA ABIRATERONE ACETATE, SUBMICRONIZED 125 MG TABLET CALQUENCE ACALABRUTINIB 100 MG CAPSULE ACAMPROSATE CALCIUM ACAMPROSATE CALCIUM 333 MG TABLET DR ACARBOSE ACARBOSE 25 MG TABLET ACARBOSE ACARBOSE 50 MG TABLET ACARBOSE ACARBOSE 100 MG TABLET ACEBUTOLOL HCL ACEBUTOLOL HCL 200 MG CAPSULE ACEBUTOLOL HCL ACEBUTOLOL HCL 400 MG CAPSULE ACETAZOLAMIDE ER ACETAZOLAMIDE 500 MG CAPSULE ER ACETAZOLAMIDE
    [Show full text]